From: Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
5 weeks | |||||
---|---|---|---|---|---|
CONTROL | DOXORUBICIN | ||||
Parameter | Unit | MEAN | SE | MEAN | SE |
LVAW;d | mm | 0.90 | 0.11 | 0.79 | 0.06 |
LVAWS;s | mm | 1.18 | 0.05 | 1.04 | 0.07 |
LVID;d | mm | 2.98 | 0.17 | 3.50* | 0.16 |
LVID;s | mm | 1.69 | 0.14 | 2.50* | 0.22 |
LVPW;d | mm | 1.03 | 0.14 | 0.81* | 0.09 |
LVPW;s | mm | 1.40 | 0.12 | 1.10* | 0.07 |
Cardiac Output | ml/min | 15.2 | 1.0 | 16.3 | 0.8 |
Ejection Fraction | % | 79.8 | 3.8 | 60.0* | 6.2 |
Fractional Shortening | % | 47.5 | 3.7 | 31.8* | 4.1 |
Heart Rate | BPM | 556.6 | 29.4 | 484.3 | 11.7 |
Stroke Volume | ul | 27.4 | 2.0 | 33.6* | 1.3 |
Volume;d | ul | 34.6 | 3.8 | 57.0* | 4.7 |
Volume;s | ul | 7.3 | 2.1 | 23.4* | 5.7 |
N = 2 m, 2f | N = 2 m, 2f |